223 related articles for article (PubMed ID: 7585592)
1. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
3. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
4. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
5. XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.
Donaldson MJ; Skoumas V; Watson M; Ashworth PA; Ryder H; Moore M; Coombes RC
Eur J Cancer; 1999 Jun; 35(6):1014-9. PubMed ID: 10533487
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
[TBL] [Abstract][Full Text] [Related]
7. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
[TBL] [Abstract][Full Text] [Related]
8. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
9. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
11. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
Sepp-Lorenzino L; Rosen N
J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
[TBL] [Abstract][Full Text] [Related]
13. Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
Omer CA; Anthony NJ; Buser-Doepner CA; Burkhardt AL; deSolms SJ; Dinsmore CJ; Gibbs JB; Hartman GD; Koblan KS; Lobell RB; Oliff A; Williams TM; Kohl NE
Biofactors; 1997; 6(3):359-66. PubMed ID: 9288406
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
16. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
[TBL] [Abstract][Full Text] [Related]
18. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Moasser MM; Rosen N
Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
[TBL] [Abstract][Full Text] [Related]
20. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
